



Final Appraisal Recommendation

Advice No: 0513 – March 2013

Linagliptin (Trajenta[®]▼) 5 mg film-coated tablets

Submission by Boehringer Ingelheim/Eli Lilly & Co Ltd

Recommendation of AWMSG

Linagliptin (Trajenta[®]▼) is recommended as an option for use within NHS Wales for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:

as monotherapy

- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment;

as combination therapy

- in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;
- in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control; and
- in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1667), which includes the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Marketing authorisation holder on first issue:	Boehringer Ingelheim/Eli Lilly & Co Ltd
Date of first issue	March 2013
Last reviewed	September 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0513:
Linagliptin (Trajenta[®]) 5 mg film-coated tablets. March 2013.